In the News
Mar 15, 2010
Affording and delivering cancer treatments has become increasingly difficult as cost of healthcare continues to rise. In response to the rising cost issue, oncologists and payers are seeking an improved drug cost to therapy benefit ratio—one with greater patient advantage, therapeutic efficacy and outcomes in exchange for their cancer drug dollar. Many stakeholders have criticized manufacturers for lack of innovation and assume prices have been intentionally set high to ensure a return on investment, and also as a way to secure the monies needed to further product development.